Combination of Serum Biomarkers to Differentiate Malignant From Benign Ovarian Tumours
article
OA: closed
CC0
Limited metadata. Only one source feed has indexed
this record so far — no abstract, full text, or open-access copy is
available through Endo Lab. The
publisher's page (linked below)
is the canonical location for the actual content. If you have institutional
access, use "Find at my library".
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (1)
References (22)
- No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting via openalex
- W180532925 via openalex
- W1553976553 via openalex
- W1968068576 via openalex
- W1980181125 via openalex
- W1989776508 via openalex
- W1992238788 via openalex
- W1997114009 via openalex
- W2029274663 via openalex
- W2037421127 via openalex
- W2052425409 via openalex
- W2061926168 via openalex
- W2064833268 via openalex
- W2096116951 via openalex
- W2096335059 via openalex
- W2098128190 via openalex
- W2102294975 via openalex
- W2108250129 via openalex
- W2126233390 via openalex
- W2138868580 via openalex
- W160481027 via openalex
- W2184669274 via openalex
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK